In the investment world, before MiFID II, essentially every institution talked to every broker, and the whole, professional market could see every research note and the forecasts in detail. This was the ‘Age of Consensus’. Everyone had the same information (well, everyone except retail investors), and this transparency helped share price formation and liquidity
10 Mar 2019
THE MONTHLY March 2019
Time Finance plc (TIME:LON), 50.5 | AJ Bell Plc (AJB:LON), 427 | Allergy Therapeutics plc (AGY:LON), 4.0 | Arbuthnot Banking Group PLC (ARBB:LON), 935 | Avacta Group PLC (AVCT:LON), 72.0 | Chamberlin plc (CMH:LON), 0 | Gateley (Holdings) Plc (GTLY:LON), 138 | Genedrive Plc (GDR:LON), 2.3 | Koovs (KOOV:LON), 0 | Oxford BioMedica plc (OXB:LON), 326 | R.E.A. Holdings plc (RE:LON), 78.8 | Shield Therapeutics Plc (STX:LON), 5.3 | Surface Transforms PLC (SCE:LON), 1.5 | Tissue Regenix Group plc (TRX:LON), 64.0 | Titon Holdings Plc (TON:LON), 65.0 | Volta Finance Limited (VTA:LON), 522 | Warpaint London PLC (W7L:LON), 549 | ValiRx PLC (VAL:LON), 2.1
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
THE MONTHLY March 2019
Time Finance plc (TIME:LON), 50.5 | AJ Bell Plc (AJB:LON), 427 | Allergy Therapeutics plc (AGY:LON), 4.0 | Arbuthnot Banking Group PLC (ARBB:LON), 935 | Avacta Group PLC (AVCT:LON), 72.0 | Chamberlin plc (CMH:LON), 0 | Gateley (Holdings) Plc (GTLY:LON), 138 | Genedrive Plc (GDR:LON), 2.3 | Koovs (KOOV:LON), 0 | Oxford BioMedica plc (OXB:LON), 326 | R.E.A. Holdings plc (RE:LON), 78.8 | Shield Therapeutics Plc (STX:LON), 5.3 | Surface Transforms PLC (SCE:LON), 1.5 | Tissue Regenix Group plc (TRX:LON), 64.0 | Titon Holdings Plc (TON:LON), 65.0 | Volta Finance Limited (VTA:LON), 522 | Warpaint London PLC (W7L:LON), 549 | ValiRx PLC (VAL:LON), 2.1
- Published:
10 Mar 2019 -
Author:
Hardman & Co Research Team -
Pages:
40
In the investment world, before MiFID II, essentially every institution talked to every broker, and the whole, professional market could see every research note and the forecasts in detail. This was the ‘Age of Consensus’. Everyone had the same information (well, everyone except retail investors), and this transparency helped share price formation and liquidity